Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
The Health Risks and Benefits of Weight-Loss Drugs
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
Major Study Exposes New Health Risks of Weight Loss Drugs
A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable risks.
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
New study on weight loss drugs
ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
A New Diabetes Treatment Is on the Horizon—But It Involves Poop
In a small randomized trial, people who took capsules containing donated gut microbiomes experienced fewer gastrointestinal ...
Gulf Times21h
New medication offers hope in preventing type 2 diabetes
A groundbreaking medication capable of preventing type 2 diabetes by up to 85% is offering new hope to those at risk, a ...
Scientists say drugs like Ozempic and Wegovy 'could slash risk of 42 health conditions'
Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions.